Drug
Emapalumab
Emapalumab: highest development phase Phase 3, developed by Swedish Orphan Biovitrum. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| Emapalumab NCT05001737 | Phase 3 | Macrophage Activation Syndrome |
| Emapalumab NCT02069899 | Phase 2/3 | Hemophagocytic Lymphohistiocytosis |
| Emapalumab NCT03311854 | Phase 2 | Macrophage Activation Syndrome |
| Emapalumab NCT04731298 | Phase 2 | Graft Failure |
Latest
No recent events.
Follow Emapalumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.